Abstract
BACKGROUND: Obstructive hypertrophic cardiomyopathy (oHCM) is associated with adverse clinical outcomes. This study aimed to evaluate real-world clinical outcomes, health care resource use, and health care costs in patients with oHCM stratified by their sociodemographic characteristics. METHODS: This retrospective, noninterventional cohort study from the Optum Market Clarity Integrated Clinical and Claims database included US adults with ≥2 medical claims with a diagnosis code for oHCM (2013-2021). Dependent on outcome measure, follow-up was variable, fixed 1-year, or fixed 5-year. Outcome measures were rate of major adverse cardiovascular events, medication use, HCRU, and health care costs. RESULTS: The study included 14 744 patients with oHCM (mean±SD age, 61.8 [14.0] years; 7504 [50.9%] female). Female patients had a higher rate of stroke than male patients (6863 versus 4773 per 100 000 patient-years), and Black patients had a higher rate of heart failure than White patients (31 084 versus 20 603). Patients in the South had a higher rate of heart failure than patients in the Northeast (25 406 versus 18 705). Patients aged 18 to 39 years had more mean±SD HCM-related ambulatory visits per patient per month (0.41 [0.48]) than older patients (eg, aged 75+, 0.27 [0.35]). Patients in the Midwest had the greatest mean±SD HCM-related health care costs per month (2071 [6420] USD) versus patients in other regions (eg, Northeast 1440 [3912] USD). Differences between groups were significant (P<0.001). CONCLUSIONS: In patients with oHCM, rate of major adverse cardiovascular events, health care resource use, and health care costs varied substantially between sociodemographic groups. Further studies are required to understand the causes of the observed variation between sociodemographic groups.